SUPRIYA LIFESCIENCE LTD

Manufactures active pharmaceutical ingredients (APIs), with a global position in anti-histamines and related therapies. The anaesthetic segment contributed 54% of Q4 FY26 revenues, and a Liquid Anesthetic product was commercialised during the year. The business is heavily export-oriented: 82% of revenue comes from exports across 120+ countries, with Europe at 40% of revenue, Asia at 33%, and Latin America at 20%. Backward integration covers 76% of revenue, supporting in-house supply of starting materials and intermediates. Five finished dosage manufacturing lines were commissioned at the Ambernath facility, marking entry into formulations alongside the core API operations at Lote, where capacity utilisation improved to 74% from 70%. The R&D pipeline includes 30 products in development, including a patented novel Semaglutide formulation, and the business is expanding into CDMO/CMO services. Materials account for 32% of revenue, the largest cost line, while capex ran at 18.4% of revenue in FY26.